Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Moodys
Mallinckrodt
Johnson and Johnson
AstraZeneca

Last Updated: April 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for OTO-104


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug OTO-104?

OTO-104 is an investigational drug.

There have been 23 clinical trials for OTO-104. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Meniere Disease, Otitis, and Otitis Media. The leading clinical trial sponsors are Otonomy, Inc., Assiut University, and OHSU Knight Cancer Institute.

There are two US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for OTO-104
TitleSponsorPhase
OTO-413 in Subjects With Speech-in-Noise Hearing ImpairmentOtonomy, Inc.Phase 1/Phase 2
OTO-313 in Subjects With Subjective TinnitusOtonomy, Inc.Phase 1/Phase 2
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's DiseaseOtonomy, Inc.Phase 3

See all OTO-104 clinical trials

Clinical Trial Summary for OTO-104

Top disease conditions for OTO-104
Top clinical trial sponsors for OTO-104

See all OTO-104 clinical trials

US Patents for OTO-104

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
OTO-104   Start Trial IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE)   Start Trial
OTO-104   Start Trial Methods and compositions for producing hepatocyte-like cells The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)   Start Trial
OTO-104   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
OTO-104   Start Trial Salts of an epidermal growth factor receptor kinase inhibitor Celgene CAR LLC (Pembroke, BM)   Start Trial
OTO-104   Start Trial 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for OTO-104

Drugname Country Document Number Estimated Expiration Related US Patent
OTO-104 Australia 2011326871 2030-11-08   Start Trial
OTO-104 Brazil 112013010157 2030-11-08   Start Trial
OTO-104 Canada 2815749 2030-11-08   Start Trial
OTO-104 China 103260625 2030-11-08   Start Trial
OTO-104 China 105288580 2030-11-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.